{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:49:32Z","timestamp":1792835372415,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472016"],"award-info":[{"award-number":["82472016"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009620","name":"Science and Technology Department of Gansu Province","doi-asserted-by":"publisher","award":["23ZDFA014"],"award-info":[{"award-number":["23ZDFA014"]}],"id":[{"id":"10.13039\/501100009620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-026-07766-w","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:14:23Z","timestamp":1768803263000},"page":"3749-3759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparative evaluation of [68Ga]Ga-FAP-2286 and [18F]FDG PET\/CT in breast cancer and initial experience with [177Lu]Lu-FAP-2286 therapy"],"prefix":"10.1007","volume":"53","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"7766_CR1","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1097\/cm9.0000000000003442","volume":"137","author":"Y Wu","year":"2024","unstructured":"Wu Y, He S, Cao M, Teng Y, Li Q, Tan N, et al. Comparative analysis of cancer statistics in China and the united States in 2024. Chin Med J. 2024;137:3093\u2013100. https:\/\/doi.org\/10.1097\/cm9.0000000000003442.","journal-title":"Chin Med J"},{"key":"7766_CR2","doi-asserted-by":"publisher","unstructured":"Panse D, Hsieh K, Arons D, Runnels J, Wassel M, Shah A, et al. The role of immunotherapy and radiation therapy in the treatment of breast cancer. Biomedicines. 2025;13. https:\/\/doi.org\/10.3390\/biomedicines13092209.","DOI":"10.3390\/biomedicines13092209"},{"key":"7766_CR3","doi-asserted-by":"publisher","unstructured":"Musket A, Davern S, Elam BM, Musich PR, Moorman JP, Jiang Y. The application of radionuclide therapy for breast cancer. Front Nuclear Med. 2024;3. https:\/\/doi.org\/10.3389\/fnume.2023.1323514.","DOI":"10.3389\/fnume.2023.1323514"},{"key":"7766_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cpet.2018.02.001","volume":"13","author":"L Lebron-Zapata","year":"2018","unstructured":"Lebron-Zapata L, Jochelson MS. Overview of breast cancer screening and diagnosis. PET Clin. 2018;13:301\u201323. https:\/\/doi.org\/10.1016\/j.cpet.2018.02.001.","journal-title":"PET Clin"},{"key":"7766_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-020-05929-3","volume":"185","author":"M Vogsen","year":"2020","unstructured":"Vogsen M, Jensen JD, Christensen IY, Gerke O, Jylling AMB, Larsen LB, et al. FDG-PET\/CT in high-risk primary breast cancer\u2014a prospective study of stage migration and clinical impact. Breast Cancer Res Treat. 2020;185:145\u201353. https:\/\/doi.org\/10.1007\/s10549-020-05929-3.","journal-title":"Breast Cancer Res Treat"},{"key":"7766_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10549-006-9159-2","volume":"98","author":"R Kumar","year":"2006","unstructured":"Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG\u2013PET in primary breast cancer. Breast Cancer Res Treat. 2006;98:267\u201374. https:\/\/doi.org\/10.1007\/s10549-006-9159-2.","journal-title":"Breast Cancer Res Treat"},{"key":"7766_CR7","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1200\/jco.2000.18.20.3495","volume":"18","author":"N Avril","year":"2000","unstructured":"Avril N, Ros\u00e9 CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and Fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495\u2013502. https:\/\/doi.org\/10.1200\/jco.2000.18.20.3495.","journal-title":"J Clin Oncol"},{"key":"7766_CR8","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s00259-025-07108-2","volume":"52","author":"W Guo","year":"2025","unstructured":"Guo W, Xu W, Meng T, Fan C, Fu H, Pang Y, et al. FAP-targeted PET\/CT imaging in patients with breast cancer from a prospective bi-center study: insights into diagnosis and clinic management. Eur J Nucl Med Mol Imaging. 2025;52:2317\u201334. https:\/\/doi.org\/10.1007\/s00259-025-07108-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7766_CR9","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of Quinoline-Based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415\u201322. https:\/\/doi.org\/10.2967\/jnumed.118.210443.","journal-title":"J Nucl Med"},{"key":"7766_CR10","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1007\/s00259-022-05706-y","volume":"49","author":"M Li","year":"2022","unstructured":"Li M, Younis MH, Zhang Y, Cai W, Lan X. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. 2022;49:2844\u201368. https:\/\/doi.org\/10.1007\/s00259-022-05706-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7766_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.122.264544","volume":"64","author":"Y Pang","year":"2023","unstructured":"Pang Y, Zhao L, Meng T, Xu W, Lin Q, Wu H, et al. PET imaging of fibroblast activation protein in various types of cancer Using68Ga-FAP-2286: comparison with18F-FDG and68Ga-FAPI-46 in a Single-Center, prospective study. J Nucl Med. 2023;64:386\u201394. https:\/\/doi.org\/10.2967\/jnumed.122.264544.","journal-title":"J Nucl Med"},{"key":"7766_CR12","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.7150\/thno.69475","volume":"12","author":"L Zhao","year":"2022","unstructured":"Zhao L, Chen J, Pang Y, Fu K, Shang Q, Wu H, et al. Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics. 2022;12:1557\u201369. https:\/\/doi.org\/10.7150\/thno.69475.","journal-title":"Theranostics"},{"key":"7766_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1097\/rlu.0000000000005297","volume":"49","author":"Y Xie","year":"2024","unstructured":"Xie Y, Ma J, Tang W, Zhang Y, Zhang C, Chen Y. Efficacy and safety evaluation of 177Lu-FAP-2286 in the treatment of advanced lung cancer. Clin Nucl Med. 2024;49:830\u20137. https:\/\/doi.org\/10.1097\/rlu.0000000000005297.","journal-title":"Clin Nucl Med"},{"key":"7766_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev A, Lindner T, Burger E-M, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation Protein\u2013Targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60:1421\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.224469.","journal-title":"J Nucl Med"},{"key":"7766_CR15","doi-asserted-by":"publisher","unstructured":"Chandekar KR, Prashanth A, Vinjamuri S, Kumar R. FAPI PET\/CT Imaging\u2014An updated review. Diagnostics. 2023;13. https:\/\/doi.org\/10.3390\/diagnostics13122018.","DOI":"10.3390\/diagnostics13122018"},{"key":"7766_CR16","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2967\/jnumed.123.267281","volume":"65","author":"B Kline","year":"2024","unstructured":"Kline B, Yadav S, Seo Y, Ippisch RC, Castillo J, Aggarwal RR, et al. 68Ga-FAP-2286 PET of solid tumors: Biodistribution, Dosimetry, and comparison with18F-FDG. J Nucl Med. 2024;65:938\u201343. https:\/\/doi.org\/10.2967\/jnumed.123.267281.","journal-title":"J Nucl Med"},{"key":"7766_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","volume":"52","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Akbari ME, Pirayesh E, Divband G, Abolhosseini Shahrnoy A, Nami R, et al. Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol Imaging. 2024;52:237\u201346. https:\/\/doi.org\/10.1007\/s00259-024-06795-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7766_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07258-3","author":"N Alan-Selcuk","year":"2025","unstructured":"Alan-Selcuk N, Akcay K, Beydagi G, Akyel R, Toklu T, Kabasakal L. [177Lu]Lu-FAP-2286 therapy in ovarian neuroendocrine carcinoma: a promising theranostic approach. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07258-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7766_CR19","doi-asserted-by":"publisher","first-page":"111195","DOI":"10.1016\/j.radonc.2025.111195","volume":"213","author":"X Bai","year":"2025","unstructured":"Bai X, Zhang N, Liu H, Xie Y, Gao B, Xu T, et al. A preliminary study on the safety and efficacy of (177)Lu-FAP-2286 in Gastrointestinal tumours with positive FAP expression. Radiother Oncol. 2025;213:111195. https:\/\/doi.org\/10.1016\/j.radonc.2025.111195.","journal-title":"Radiother Oncol"},{"key":"7766_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2967\/jnumed.123.266798","volume":"65","author":"E Sahin","year":"2024","unstructured":"Sahin E, Kus T, Aytekin A, Uzun E, Elboga U, Yilmaz L, et al. 68Ga-FAPI PET\/CT as an alternative to18F-FDG PET\/CT in the imaging of invasive lobular breast carcinoma. J Nucl Med. 2024;65:512\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.266798.","journal-title":"J Nucl Med"},{"key":"7766_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s12149-021-01616-5","volume":"35","author":"H K\u00f6mek","year":"2021","unstructured":"K\u00f6mek H, Can C, G\u00fczel Y, Oru\u00e7 Z, G\u00fcndo\u011fan C, Yildirim \u00d6A, et al. 68Ga-FAPI-04 PET\/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET\/CT. Ann Nucl Med. 2021;35:744\u201352. https:\/\/doi.org\/10.1007\/s12149-021-01616-5.","journal-title":"Ann Nucl Med"},{"key":"7766_CR22","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","volume":"49","author":"D Zboralski","year":"2022","unstructured":"Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49:3651\u201367. https:\/\/doi.org\/10.1007\/s00259-022-05842-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7766_CR23","doi-asserted-by":"publisher","unstructured":"Xiang F, Zhang Y, Tan X, Zhang J, Li T, Yan Y, et al. Comparison of 68Ga-FAP-2286 and 18F-FDG PET\/CT in the diagnosis of advanced lung cancer. Front Oncol. 2024;14. https:\/\/doi.org\/10.3389\/fonc.2024.1413771.","DOI":"10.3389\/fonc.2024.1413771"},{"key":"7766_CR24","doi-asserted-by":"publisher","first-page":"1358070","DOI":"10.3389\/fonc.2024.1358070","volume":"14","author":"T Li","year":"2024","unstructured":"Li T, Zhang J, Yan Y, Tan M, Chen Y. Applications of FAPI PET\/CT in the diagnosis and treatment of breast and the most common gynecologic malignancies: a literature review. Front Oncol. 2024;14:1358070. https:\/\/doi.org\/10.3389\/fonc.2024.1358070.","journal-title":"Front Oncol"},{"key":"7766_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4274\/mirt.galenos.2024.99705","volume":"33","author":"P Singh","year":"2024","unstructured":"Singh P, Singhal T, Parida GK, Rahman A, Agrawal K. Diagnostic performance of FAPI PET\/CT vs. (18)F-FDG PET\/CT in evaluation of liver tumors: A systematic review and Meta-analysis. Mol Imaging Radionucl Ther. 2024;33:77\u201389. https:\/\/doi.org\/10.4274\/mirt.galenos.2024.99705.","journal-title":"Mol Imaging Radionucl Ther"},{"key":"7766_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","volume":"38","author":"D Groheux","year":"2011","unstructured":"Groheux D, Giacchetti S, Moretti JL, Porcher R, Espie M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426\u201335. https:\/\/doi.org\/10.1007\/s00259-010-1640-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7766_CR27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/cncr.23226","volume":"112","author":"S Basu","year":"2007","unstructured":"Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and Estrogen receptor\u2010positive\/progesterone receptor\u2010positive\/HER2\u2010negative breast carcinoma using quantitative fluorine\u201018 fluorodeoxyglucose\/positron emission tomography imaging parameters. Cancer. 2007;112:995\u20131000. https:\/\/doi.org\/10.1002\/cncr.23226.","journal-title":"Cancer"},{"key":"7766_CR28","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s12149-021-01672-x","volume":"35","author":"U Elboga","year":"2021","unstructured":"Elboga U, Sahin E, Kus T, Cayirli YB, Aktas G, Uzun E, et al. Superiority of (68)Ga-FAPI PET\/CT scan in detecting additional lesions compared to (18)FDG PET\/CT scan in breast cancer. Ann Nucl Med. 2021;35:1321\u201331. https:\/\/doi.org\/10.1007\/s12149-021-01672-x.","journal-title":"Ann Nucl Med"},{"key":"7766_CR29","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1007\/s00259-021-05378-0","volume":"48","author":"K Dendl","year":"2021","unstructured":"Dendl K, Koerber SA, Finck R, Mokoala KMG, Staudinger F, Schillings L, et al. 68Ga-FAPI-PET\/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging. 2021;48:4089\u2013100. https:\/\/doi.org\/10.1007\/s00259-021-05378-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7766_CR30","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.06.010","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Abdlkadir AS, Ruzzeh S, Abdulrahman M, Moghrabi S, Ahmed R, et al. [177Lu]Lu-FAPI radioligand therapy: emerging horizons and clinical promise in solid tumors: A comprehensive review. Semin Nucl Med. 2025. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.06.010.","journal-title":"Semin Nucl Med"},{"key":"7766_CR31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","volume":"63","author":"RP Baum","year":"2022","unstructured":"Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, et al. Feasibility, Biodistribution, and preliminary dosimetry in Peptide-Targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: First-in-Humans results. J Nucl Med. 2022;63:415\u201323. https:\/\/doi.org\/10.2967\/jnumed.120.259192.","journal-title":"J Nucl Med"},{"key":"7766_CR32","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","volume":"46","author":"M Assadi","year":"2021","unstructured":"Assadi M, Rekabpour SJ, Jafari E, Divband G, Nikkholgh B, Amini H, et al. Feasibility and therapeutic potential of 177Lu-Fibroblast activation protein Inhibitor-46 for patients with relapsed or refractory cancers: A preliminary study. Clin Nucl Med. 2021;46:e523\u201330. https:\/\/doi.org\/10.1097\/RLU.0000000000003810.","journal-title":"Clin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07766-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07766-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07766-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:25:51Z","timestamp":1777274751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07766-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7766"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07766-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consents were obtained from the included subjects for participation in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that all human participants involved in this study have signed the consent form and agreed to the publication of their medical imaging.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}